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Executive Summary 
 
A request was received from the Battelle Memorial Institute, Pacific Northwest 
Laboratories Office of Small Business Programs to perform a review of the 
toxicity and safe use of guanidine.  An extensive information search was 
conducted to locate toxicity and safety data for this compound. Because so little 
information was found on guanidine, the search was extended to the most 
common guanidine compound that is commercially available and chemically 
similar: guanidine hydrochloride.  At the request of John Holbrook, urea was also 
included in this review, since guanidine decomposes to urea and carbon dioxide. 
 
Based on the published data, guanidine should be considered a toxic compound 
by oral ingestion.  No data is available for inhalation exposures. It is also a 
significant irritant to the eyes, skin, and lungs; has desiccant effects (is very 
drying to human tissue) by virtue of being hygroscopic; and in solution the pH 
may approach corrosivity, depending on the concentration. Guanidine does not 
appear to be absorbed through the skin.  
 
There are no published studies detailing the effects of guanidine on humans; the 
only information on human exposure comes from the pharmaceutical industry, 
where guanidine hydrochloride is used as an orally administered drug. That data 
indicates that guanidine has significant effects on the gastrointestinal and 
nervous system as well as the desired therapeutic effect on the neuromuscular 
systems in persons with a rare disease, the Eaton-Lambert myasthenic 
syndrome.  This effect on the neuromuscular system could be harmful in normal 
persons. The doses of guanidine hydrochloride used in medical treatment are 
much higher than would be expected from occupational exposure, and are oral 
doses as opposed to the inhalation doses expected in industry.  However, 
caution is still warranted due to the potential severity of the effects. Controlling 
exposures to prevent irritant effects will keep doses low enough to minimize any 
concerns about these effects.  
 
Because of its irritant properties, exposure to the skin, lungs, and eyes must be 
prevented.  This can best be accomplished by the use of engineering controls 
such as enclosed systems and local exhaust ventilation to minimize dust 
generation. Personal protective equipment should be utilized if engineering 
controls cannot control exposures. Gloves should be worn to prevent skin contact 
when handling guanidine; no gloves have been tested for resistance to guanidine 
or guanidine hydrochloride, but nitrile gloves resist corrosives such as sodium 
hydroxide and should be a reasonable choice if no other chemicals are used in 
the process.   
 
Based on the published data, urea should be considered relatively non-toxic.  It 
may be slightly irritating to the eyes, skin, and lungs. Controlling exposures for 
the harmful effects of guanidine should also control for any harmful effects of 
urea.  
Guanidine toxicity P. 2 4/3/2006 
 
Introduction 
 
A request was received from the Battelle Memorial Institute, Pacific Northwest 
Laboratories Office of Small Business Programs to perform a review of the 
toxicity and safe use of guanidine.  At the request of John Holbrook, urea was 
also included in this request. Guanidine decomposes to urea and carbon dioxide, 
and exposures to urea might be expected in facilities handling guanidine. 
 
Methods 
 
An extensive information search was conducted to locate toxicity and safety data 
for these compounds. The information sources are listed in the References and 
include national biomedical and toxicology databases, chemistry reference 
books, and chemical manufacturers. References will be retained in our files.  
 
Because so little information was found on guanidine, the search was extended 
to guanidine hydrochloride, the hydrochloride salt of guanidine, for which more 
information is available. Because guanidine hydrochloride is chemically very 
similar to guanidine, toxicity information for guanidine hydrochloride is likely to be 
analogous to guanidine; the U.S. Army used guanidine hydrochloride as a 
surrogate for guanidine in toxicological testing conducted in the 1980s. Results 
are presented for the two compounds as a group.  
 
Results 
 
A. Description and uses of guanidine and guanidine hydrochloride 
 
Guanidine is a strong organic base that is found in the urine as a normal product 
of protein metabolism. It is also used as a protein denaturant in biomedical and 
molecular biology research. It is found naturally in small amounts in a number of 
foods, including turnips, mushrooms, corn, rice, and mussels. In industry, 
guanidine and its derivatives are used in manufacture of plastics, resins, 
photochemicals, fungicides, rubber chemicals, and disinfectants. 
 
Guanidine hydrochloride, the hydrochloride salt of guanidine, is commercially 
available. It is a common chemical intermediate in manufacturing, as noted 
above. It has been used to produce nitroguanidine, a component of rocket 
propellants. 
 
Guanidine hydrochloride is also available as an orally administered human drug.  
Its use is for the treatment of muscle weakness and easy fatigue caused by a 
rare disease known as the myasthenic syndrome of Eaton-Lambert, which is 
associated with small-cell carcinoma of the lung. The precise action of the drug is 
not known, but it apparently acts to enhance the release of acetylcholine and to 
slow the rates of depolarization and repolarization of muscle cell membranes.  
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Synonyms for guanidine include carbamidine; carbamamidine; iminourea; 
imidourea; aminoformamidine; and aminomethanamidine. 
 
Synonyms for guanidine hydrochloride include guanidium chloride; guanidium 
hydrochloride; iminourea hydrochloride; carbamidine hydrochloride; 
aminoformamidine hydrochloride; and aminomethanamidine hydrochloride. 
 
B. Description and uses of Urea 
 
Urea is made in the liver as an end-product of protein metabolism and excreted 
in urine. Humans excrete up to 30 grams of urea per day in the urine. Urea 
occurs normally in skin.  It is used in a variety of industrial and consumer 
applications: in the manufacturing of urea-formaldehyde resins and foams; as a 
component of animal feeds, where it supplies nitrogen; in hand lotions and 
topical pharmaceutical preparations, where it promotes rehydration of dry skin 
and aids in debridement of damaged tissue; and as a protein denaturant in 
molecular biology research. Urea is accepted as a “Generally Recognized as 
Safe” food additive and is also used as a fermentation aid in foods and 
beverages.  Urea has limited uses in medicine.   
 
Urea is widely used in industry, and industrial experience in the United States 
has not suggested problems related to urea exposure.   
 
Synonyms for urea include carbamide; ureaphil; ureapearl; ureophil; 
carbamimidic acid; carbonyl diamide; carbonyldiamide. 
  
C. Physical Properties  
 
The physical properties of guanidine, guanidine hydrochloride, and urea are 
described in Table 1.  
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Table 1 
Physical Properties of Guanidine, Guanidine Hydrochloride, and Urea 
 
Property  Guanidine  Guanidine 
Hydrochloride 
Urea 
CAS number 113-00-8 50-01-1 57-13-6 
Molecular 
formula 
CH5N3 CH6ClN3 CH4N20 
Molecular weight 59.071 95.53 60.06 
Physical state Deliquescent 
crystalline mass 
White crystalline 
powder 
Colorless to white crystals 
or powder 
Melting point   ~ 50 C 180-185 C 132.7 C 
Boiling point  > 160 C 
(decomposes) 
>250 C 
(decomposes) 
No 
Specific gravity Not reported in 
literature 
1.34 1.32 
pH Not reported in 
literature; expected 
to be strongly basic 
(>10) in solution 
6.5 (5% solution) 7.2 (10% solution) 
Solubility in water Soluble 200g/100g Soluble 
Solvent solubility Soluble in alcohol Soluble in alcohol Soluble in alcohol  
Stability  Hygroscopic Hygroscopic.  
Stable under 
normal conditions. 
Hygroscopic. Stable under 
normal conditions. 
 
 
D. Toxic Effects of Guanidine, Guanidine Hydrochloride, and Urea 
 
The following definitions are used in this section: 
 
LDLO/LCLO – the lowest published lethal dose or concentration of a substance, 
determined by testing on animals. The lowest lethal dose may vary by species of 
animal. 
 
LD50/LC50 – the dose or concentration of a chemical that kills 50% of a sample 
population of animals.  LD50/LC50 values in different types of animals and in 
different routes of exposure (oral, injected) are not directly comparable.  LD50 
values are widely used as a measure of the potential toxicity of a chemical.   
Reports of the effects suffered by animals during the testing and the findings on 
necropsy are often cited as health effects that may occur in humans, when no 
human data exists. 
 
Draize Test - a test that measures how irritating a chemical is to the eye or skin.  
The chemical is applied to the skin or eye of animals, typically rabbits.  
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Buehler Test – a test the measures whether a chemical produces sensitization 
(allergic) skin responses on repeated skin exposure to the chemical. 
 
Toxicity data was obtained from the Registry of Toxic Effects of Chemical 
Substances (RTECS), TOXLINE/TOXNET, and the National Library of 
Medicine’s Specialized Information Services.  
 
Toxicity data is shown for each substance in separate tables.  LD50 data is 
shown first in each table. 
 
Table 2 
Guanidine – Toxicity Data 
 
Test Type Species Route Reported Dose Year of 
Study 
LD50 Mouse IP injection 350 mg/kg 1966 
LDLO Frog SC injection 3000 mg/kg 1935 
LDLO Mouse SC injection 266 mg/kg 1935 
LDLO Rabbit Oral  500 mg/kg 1989 
LDLO Rat SC injection 150 mg/kg 1935 
IP – Intraperitoneal (in the abdomen) 
SC – Subcutaneous (under the skin) 
Guanidine toxicity P. 6 4/3/2006 
 
 
Table 3 
Guanidine Hydrochloride – Toxicity Data 
 
Test Type Species Route Reported Dose/Effect Year of 
Study 
LD50 Mouse Oral 571 mg/kg; muscle 
contraction, shortness of 
breath, irritability, altered 
sleep patterns 
1993 
LD50 Mouse IP injection  500 mg/kg unknown 
LD50 Rat Oral 475 mg/kg ; excitement, 
diarrhea, altered sleep 
1986 
LDLO Rat SC injection 404 mg/kg 1926 
LDLO Unspecified Oral 300 mg/kg; muscle 
contraction, shortness of 
breath, convulsions  
1931 
LDLO Guinea pig SC injection 100 mg/kg 1935 
LDLO Guinea pig  IV injection 500 mg/kg 1928 
LDLO Guinea pig IA injection 500 mg/kg 1928 
LDLO Dog SC injection 200 mg/kg 1935 
LD Rabbit Dermal >2000 mg/kg; no deaths; 
severe skin irritation 
1993 
Draize Rabbit Ocular Moderate eye irritation 1987 
Buehler  Guinea Pig Dermal No skin sensitization 1984 
Draize Guinea Pig Dermal Severe skin irritation 1986 
IP – intraperitoneal (in the abdomen) 
SC – subcutaneous (under the skin) 
IV – intravenous (in the vein) 
IA – intraarterial (in the artery) 
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Table 4 
Urea – Toxicity Data 
 
Test Type Species Route Reported Dose/Effect Year of 
Study 
LD50 Rat SC 8200 mg/kg; altered sleep, 
changes in motor activity 
1977 
LD50 Rat Oral 8471 mg/kg 1986 
LD50 Rat IV injection 5300 mg/kg; altered sleep, 
changes in motor activity 
1977 
LD50 Rat  Intratracheal 567 mg/kg; convulsions, 
shortness of breath, 
methemoglobinia, 
carboxyhemobinia 
1986 
LD50 Rat IP injection >5000 mg/kg 1967 
LD50 Mouse SC injection 9200 mg/kg; altered sleep, 
changes in motor activity 
1977 
LD50 Mouse Oral  11,000 mg/kg 1977 
LD50 Mouse IV injection 4600 mg/kg; altered sleep, 
changes in motor activity 
1977 
LDLO Dog IV injection 3000 mg/kg 1935 
LDLO Dog SC injection 3000 mg/kg 1935 
LDLO Goat/sheep Oral 511 mg/kg; tetany, 
shortness of breath, 
changes in salivary glands 
1948 
LDLO Frog SC injection 600 mg/kg 1935 
LDLO Mouse IP injection 6608 mg/kg; convulsions, 
coma 
1936 
LDLO Pigeon SC injection 14,800 mg/kg 1931 
LDLO Rabbit IV injection 4800 mg/kg 1935 
LDLO Rabbit Oral 10,000 mg/kg; 
degenerative brain 
changes, hemorrhage, 
changes in 
trachea/bronchi 
1953 
LDLO Rabbit SC injection 3000 mg/kg 1935 
Draize Human Dermal Mild irritation Unknown 
IP – intraperitoneal (in the abdomen) 
SC – subcutaneous (under the skin) 
IV – intravenous (in the vein) 
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Summary and Interpretation of Findings  
 
A. Guanidine and guanidine hydrochloride 
 
Based on the available toxicity data, guanidine and guanidine hydrochloride both 
fall into the category of toxic compounds, based on oral (ingestion) data. There is 
almost no data on guanidine, and minimal data for guanidine hydrochloride, but 
the test results for each compound are relatively consistent, and when the results 
for guanidine and guanidine hydrochloride are compared, they are also similar. 
For this reason, it is reasonable to consider that the toxicity of guanidine 
hydrochloride is similar to that of guanidine.  There is no data based on inhalation 
exposure, which is the most common route of exposure in industry.  
 
The existing toxicity data is based on animal studies, and there could be slightly 
different effects or dose relationships in humans.   
 
In the laboratory or industrial setting we are primarily concerned about exposures 
from inhalation and skin contact, rather than ingestion, and it is important to 
anticipate what health effects might occur on exposure. There is limited health 
effects data available for guanidine hydrochloride; however, these effects likely 
extend to guanidine as well. Of course, guanidine should not be swallowed and 
inadvertent hand-to-mouth transfer should be avoided. 
 
Guanidine hydrochloride is very irritating to the skin and eyes.   Since guanidine 
hydrochloride is irritating to the skin and eyes, it is also likely to be irritating to the 
lungs if inhaled.  In addition, its hygroscopic properties mean that it may cause 
desiccation, or severe drying, of the tissues of eye, skin, and lung on direct 
contact.  Guanidine in aqueous solutions is likely to be highly alkaline, which 
means that the solutions could be corrosive, causing burning and scarring of 
tissue exposed to the liquid.  Corrosives cause more severe injury than materials 
that are irritating, although one should not underestimate irritant effects, which 
can be quite serious and disabling.  
 
There is limited evidence that guanidine is not absorbed to any significant degree 
through the skin in animals.  However, the severe irritant effects of guanidine on 
the skin and eyes mean that exposures via the airborne and skin exposure 
routes must be minimized.  This can best be achieved by limiting the transfer and 
delivery of guanidine to enclosed systems, or operations carried out under local 
exhaust ventilation. Personal protective equipment such as protective eyewear, 
respirators, and gloves may be necessary depending on the level of engineering 
control that can be achieved.  More information on the planned work process 
would be needed to prescribe the exact respirator and gloves; for instance, are 
any carrier agents or other chemicals used in the process, will the material be 
handled dry, will aerosols be generated, etc.   
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Shortness of breath, gastrointestinal effects such as diarrhea, and increased 
muscle contractility were reported in test animals and might occur in humans as 
well.  Shortness of breath might occur upon inhalation exposure due to irritant 
effects. Gastrointestinal effects would most likely be seen with ingestion.   
 
It is unclear whether inhalation could produce a high enough dose for increased 
muscle contractility; this effect would most likely occur with ingestion. This is an 
effect which is desired when guanidine hydrochloride is used as a 
pharmaceutical agent, but could be dangerous to a normal person because of 
potential effects on the cardiac muscle.   When used as medical treatment, the 
therapeutic dose of guanidine hydrochloride is from 10-15 mg/kg (5 to 7 mg/lb) of 
body weight per day, not to exceed a daily dose of 30 mg/kg.  For a 150 pound 
this would be a daily dose ranging from 750 to 1050 mg.  Drug literature indicates 
that individual tolerance is highly variable for this drug and side effects on the 
neurological, gastrointestinal, skin, renal, hepatic, and cardiac systems are 
common, with the gastrointestinal and neurological effects of nausea/ diarrhea 
and nervousness/mood changes/irritability being the most frequently observed. 
Fatal cases of bone-marrow suppression have been reported in patients who 
took high doses of the drug.  It would be highly unlikely that an exposure to even 
the lower range of the therapeutic dose of guanidine would occur in industrial 
use, but these effects provide additional evidence that exposure should be 
minimized. 
 
Limited evidence does not indicate that guanidine or guanidine hydrochloride 
have any mutagenic (damage to DNA) effects. 
 
There have been no studies to determine whether guanidine and guanidine 
hydrochloride cause cancer.  These two compounds are not listed or classified in 
any carcinogen categories as by the International Agency for Research on 
Cancer (IARC), the National Toxicology Program, or the American College of 
Governmental Industrial Hygienists. 
 
There are no published studies on reproductive effects of guanidine or guanidine 
hydrochloride.  
 
There are no occupational exposure limits for guanidine or guanidine compounds 
from the Occupational Safety and Health Administration, the American 
Conference of Governmental Industrial Hygienists, or the American Industrial 
Hygiene Association.  An appropriate exposure limit to apply, by analogy, to 
control the respiratory and skin irritant properties of guanidine hydrochloride, 
would be an exposure limit similar to that of sodium hydroxide, another strong 
base. That exposure limit is 2 milligrams per cubic meter of air, as a ceiling 
concentration, averaged over a 15-minute period.    
 
There are no public exposure limits for guanidine or guanidine compounds listed 
by the Environmental Protection Agency. 
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B. Urea 
 
Urea falls into the category of non-toxic, based on the oral data. No studies of 
toxicity from inhalation exposure were found in the literature. 
 
Urea is noted to cause slight irritation of the skin, lungs, and eyes; however, 
urea’s irritant effects appear to be significantly less than that of guanidine.  
 
Limited evidence indicates that urea may have some mutagenic (damage to 
DNA) effects. The significance of these findings and how they apply to 
occupational exposures is unclear. 
 
There have been several studies to determine whether urea causes cancer.  
Urea is not listed or classified in any carcinogen categories by the International 
Agency for Research on Cancer (IARC), the National Toxicology Program, or the 
American College of Governmental Industrial Hygienists. 
 
No studies have identified adverse reproductive effects from inhaled, ingested, or 
skin/eye exposures to urea in animals or humans. 
 
There are no occupational exposure limits for urea compounds from the 
Occupational Safety and Health Administration, the American Conference of 
Governmental Industrial Hygienists.  The American Industrial Hygiene 
Association has published a Workplace Environmental Exposure Level for urea 
of 10 milligrams urea per cubic meter of air, averaged over an 8-hour workday, 
which is based on irritant effects.    
 
There are no public exposure limits for urea listed by the Environmental 
Protection Agency. 
 
Conclusions and Recommendations 
 
Based on the published data, guanidine should be considered a toxic compound 
by oral ingestion. No data is available for inhalation exposures. It is also a 
significant irritant to the eyes, skin, and lungs; has desiccant effects by virtue of 
being hygroscopic; and in solution the pH may approach corrosivity, depending 
on the concentration. Guanidine does not appear to be absorbed through the 
skin.  
 
There are no published studies detailing the effects of guanidine on humans; the 
only information on human exposure comes from the pharmaceutical industry, 
where guanidine hydrochloride is used as an orally administered drug. That data 
indicates that guanidine has significant effects on the gastrointestinal and 
nervous system as well as the desired therapeutic effect on the neuromuscular 
systems in persons with a rare disease, the Eaton-Lambert myasthenic 
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syndrome.  This effect on the neuromuscular system could be harmful in normal 
persons.  The doses of guanidine hydrochloride used in medical treatment are 
much higher than would be expected from occupational exposure, and are oral 
doses as opposed to the inhalation doses expected in industry.  However, 
caution is still warranted due to the potential severity of these effects. Controlling 
exposures to prevent irritant effects will keep doses low enough to minimize any 
concerns about these effects.  
 
Because of its irritant properties, exposure to the skin, lungs, and eyes must be 
prevented.  This can best be accomplished by the use of engineering controls 
such as enclosed systems and local exhaust ventilation to minimize dust 
generation. Personal protective equipment should be utilized if engineering 
controls cannot control exposures. Gloves should be worn to prevent skin contact 
when handling guanidine; no gloves have been tested for resistance to guanidine 
or guanidine hydrochloride, but nitrile gloves resist corrosives such as sodium 
hydroxide and should be a reasonable choice if no other chemicals are used in 
the process.  If other chemicals are also used, a manufacturer’s glove chart 
should be consulted, or you may contact the author for assistance. 
 
Based on the published data, urea should be considered relatively non-toxic. It 
may be slightly irritating to the eyes, skin, and lungs. Controlling exposures for 
the harmful effects of guanidine should also control for any harmful effects of 
urea.  
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